BetterNight’s Post

🔎Tirzepatide Reduced Sleep Apnea Severity in Patients with Obesity🔎 Recent results from the phase 3 SURMOUNT-OSA clinical trial, published on April 17, highlight the effectiveness of tirzepatide in significantly reducing the apnea-hypopnea index (AHI) in adults with obesity and moderate-to-severe obstructive sleep apnea (OSA). Conducted by Eli Lilly, these multi-center, randomized, double-blind studies involved 469 participants and spanned across various international locations. Key findings include: 🔹 In patients not using positive airway pressure (PAP) therapy, tirzepatide reduced the AHI by 27.4 events per hour from baseline, compared to 4.8 events per hour with placebo. 🔹 For those on PAP therapy, tirzepatide achieved a reduction of 30.4 events per hour from baseline, versus 6.0 with placebo. 🔹 The treatment led to significant weight loss, with an average reduction close to 20% across both study groups. These results underscore tirzepatide's potential in treating OSA with obesity because tirzepatide aids in weight loss and also addresses the underlying airway blockages that contribute to OSA, thus offering a dual-benefit approach. Eli Lilly is preparing for global regulatory submissions based on these compelling outcomes. #SleepApnea #ObesityTreatment #ClinicalTrials #HealthcareInnovation For further information, click on the press release below. https://lnkd.in/geeyuUKk 📧 Need expert medical writing help? For details on our services or a project quote, contact us at https://lnkd.in/eUd9SdiB.

Thank you Arash Nayeri MD for providing this valuable information. Obstructive sleep apnea (OSA) is a weight related comorbidity and a well known risk factor for #cardiovascular disease. Treatment with CPAP masks has for long been standard of care, however, tolerance is poor for many patients. In the seminal Surmount-OSA trial, #Tirzepatide (branded as Zepbound or Mounjaro) was shown to markedly reduce sleep apnea events and improve sleep apnea related comoribidites such as systemic inflammation and #hypertension. This likely presents a new age in sleep medicine and yet another piece of evidence supporting weight control as the key to treat weight related comorbidities. https://lnkd.in/gCnNGcdJ

As today is #WorldSleepDay it seems a fitting time to post a link to our latest case study describing a market assessment for a novel personalised sleep apnoea lifestyle intervention. The market research assessment was completed for the University of Essex and explored clinical needs and commercial opportunities for the intervention. The project involved interviewing General Practitioners, Respiratory Consultants, Cardiologists and sleep clinic practitioners as well as industry representatives from the sleep apnoea diagnostic and therapy markets. #marketresearch https://loom.ly/C_69ULM

New Sleep-Loss Scale Proves Effective in Measuring Itch Impact on Sleep for Atopic Dermatitis Patients Researchers have validated a new Sleep-Loss Scale that measures how itch impacts sleep in atopic dermatitis

ResMed presented 13 new clinical studies at Sleep 2024, highlighting findings on insomnia prevalence and the impact of PAP therapy on patients with comorbid insomnia and sleep apnea. (COMISA). Key insights included the widespread prevalence of insomnia, reduced hospital visits among COMISA patients adhering to PAP therapy, and higher rates of depression and lower PAP adherence among women with OSA. Key Takeaways: Prevalence of Insomnia: Approximately 17% of adults across Northern America, Latin America, and the Caribbean suffer from insomnia, underscoring the need for prioritizing sleep health in public health initiatives. Impact of PAP Therapy on COMISA Patients: Adherence to PAP therapy significantly reduces hospitalizations and emergency room visits among patients with comorbid insomnia and sleep apnea, improving overall health outcomes. OSA and Depression: Women with OSA are more likely to experience depression and demonstrate lower adherence to PAP therapy, highlighting the need for targeted interventions to improve treatment compliance in this group. Read the full article below: https://lnkd.in/ef-YwUNu #Medexec #Sleep2024 #SleepApnea #ResMed

For pulmonologists, early detection and comprehensive management of sleep apnea in hypertension patients is key. This improves patient health outcomes significantly. We take a closer look at managing sleep apnea and hypertension in our latest blog ➡️ https://lnkd.in/geZhWf5z. #PulmonaryMedicine #SleepApnea #Hypertension #PatientCare #betternight 

As I travel the country and work with providers, I'm truly amazed at the number of providers who make statements like "we don't have many sleep patients in our practice." Although screening for sleep disordered breathing has become more prevalent of the last couple of decades, we still have work to do to educate on good screening practices and the correlation between OSA and other comorbidities. One point of education for providers/offices who may believe the statement above is to educate on Hypertension and it's correlation to OSA. They seem to be dialed in to their hypertensive patients. So helping them to understand that approximately 75% of treatment-resistant hypertension (TRH) patients have underlying OSA can help further identify those patients who need help with sleep disordered breathing and help get them diagnosed and on therapy. We are here to help!

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity. I want to know the mechanism: is there a direct action of the drug that inhibits apnea episodes, or is the OSA relief due to the weight loss? The study protocol shows the endpoints only at 52 weeks, but I can't help but wonder how long it took for the reduction in OSA severity to occur. Did OSA reduction accompany or precede weight loss? I look forward to the full data presentation! +++ 👋 I’m Chris, a medical strategist, writer, and founder of Quill Science LLC. We use accurate and engaging storytelling to amplify the benefits of cutting-edge scientific and medical advances. 🌐 Check out www.quillscience.com and book a free discovery call. 💡 Follow me for science and medical news, perspectives, and career posts.

With #Inspire therapy, i.e. stimulation of the hypoglossal nerve (#HGNS), very high clinical success rates can be achieved in obstructive sleep apnoea (#OSA) within twelve months. This is the encouraging result of a recently published meta-analysis by Kim et al (1).   The Sher criteria should be used to determine whether the HGNS is clinically effective (2). These include the reduction of the apnoea-hypopnoea index (#AHI), improvement of oxygen saturation during sleep (Oxygen Desaturation Index, #ODI), reduction of daytime sleepiness (Epworth Sleepiness Scale, #ESS) and the subjective assessment of sleep quality (Functional Outcome of Sleep Questionnaire, #FOSQ).   In addition, Kim et al. (2) only included HGNS studies that met other quality criteria, including the Newcastle-Ottawa Scale (#NOS) and the Cochrane Risk of Bias Tool. The effect sizes determined by Kim et al. should thus be highly relevant for clinicians as well.   A total of 44 studies and data from 8,760 patients were analysed. It was found that the AHI twelve months after implantation was below 5 in 47% of patients, below 10 in 72% and below 15 in 82%. Overall success rates according to Sher criteria were 80% within 12 months after implantation and 73% between 12 and 36 months.   (1) Kim DH, Kim SW, Han JS et al. Otolaryngol Head Neck Surg. 2024 Mar;170(3): 736–746. (2) Sher AE, Schechtman KB, Piccirillo JF. Sleep. 1996; 19(2), 156–177.   #UAS #sleep ___ (Individual treatment results may vary. For professional use only. Inspire therapy can be used in patients with moderate to severe sleep apnoea who have been medically confirmed to have failed or not tolerated PAP treatment (e.g. with a #CPAP mask) and who are medically suitable for Inspire therapy. For important information about Inspire therapy and its delivery, risks and safety, visit https://lnkd.in/e8iAwxVs. For further advice on safety precautions, visit the respective Inspire country websites due to the different requirements.) 

😴💉Mounjaro not such a snore💉😴 The results of SURMOUNT-OSA published recently show promising outcomes for patients living with moderate-severe obstructive sleep apnoea (OSA) and obesity. https://lnkd.in/eJabZJYb 🔬The trial, sponsored by Eli Lilly and Company, consisted of two 52-week, phase 3, multi-center, parallel-group, double-blind, randomised, controlled trials conducted at 60 sites across nine countries in adults with moderate-to-severe obstructive sleep apnoea and obesity. One trial consisted of patients receiving positive airway pressure (PAP) at baseline (for at least 3 months prior) and the other trial were not receiving PAP (unable or unwilling). In both trials the participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. 👨🏻Demographics 👩🏽🦱 Key exclusion criteria was type 1 and type 2 diabetes Average age of participants 48-51 Average BMI 39 67-72 % participants male The primary endpoint was the change in AHI (the apnoea–hypopnoea index - the number of apnoeas and hypopnoeas during an hour of sleep) from baseline. However multiple secondary endpoints also emerged, which were in keeping with our prior knowledge. 📈The study showed that tirzepatide reduced the AHI by up to 29.3 events per hour (a 58.7% change from baseline) compared to up to 5.3 events per hour (a 3.0% change from baseline) in the placebo group. Results also showed reduced body weight, hypoxic burden, CRP, and systolic blood pressure and improved patient reported sleep outcomes (PROMIS). This is very encouraging data however I think more research is needed before it would be recommended a sole treatment for OSA, however it is clear that is will be an effective option for those suffering from this often debilitating condition. 🛌 I wonder is this currently recommended in any sleep clinics in the UK just now? #OSA #sleepapnoea #sleepmedicine #tirzepatide #mounjaro #weightloss #obesitymedicine #elililly #metabolichealth #cardiovascularhealth